不同剂量重组人干扰素α-1b雾化吸入治疗重症手足口病患儿的效果观察

Observation on the Effects of Atomized Inhalation of Different Doses of Recombinant Human Interferonα-1b in the Treatment of Children with Severe Hand-Foot-Mouth Disease

目的探讨不同剂量重组人干扰素α-1b雾化吸入治疗重症手足口病患儿的临床效果。方法回顾性分析2018年10月至2020年1月我院收治的85例重症手足口病患儿的临床资料,按照重组人干扰素α-1b剂量的不同分为A组(2μg/kg,28例)、B组(3μg/kg,28例)和C组(4μg/kg,29例)。比较三组治疗前后的血清S-100B蛋白、NSE水平,比较三组的退热时间及皮疹消退时间。结果治疗5 d后,三组的血清S-100B蛋白、NSE水平均较治疗前降低,C组的血清NSE水平显著低于A组、B组(P<0.05)。C组的退热时间及皮疹消退时间显著短于A组、B组(P<0.05)。结论重组人干扰素α-1b雾化吸入治疗重症手足口病可减轻患儿的中枢神经损伤,高剂量治疗可更有效地降低患儿血清NSE水平,缩短退热时间及皮疹消退时间。

Objective To explore the clinical effects of atomized inhalation of different doses of recombinant human interferonα-1b in the treatment of children with severe hand-foot-mouth disease.Methods The clinical data of 85 children with severe hand-foot-mouth disease admitted to our hospital from October 2018 to January 2020 were retrospectively analyzed.All cases were divided into group A(2μg/kg,28 cases),group B(3μg/kg,28 cases)and group C(4μg/kg,29 cases)according to different doses of recombinant human interferonα-1b.The levels of serum S-100B protein and NSE before and after treatment,and the antifebrile time and rash resolution time were compared among 3 groups.Results After 5 days of treatment,the levels of serum S-100B protein and NSE of three groups were lower than those before treatment;The serum NSE level in group C was significantly lower than that in group A and group B(P<0.05).The antifebrile time and rash resolution time in group C were significantly shorter than those in groups A and group B(P<0.05).Conclusions Atomized inhalation of recombinant human interferonα-1b in the treatment of severe hand-foot-mouth disease can alleviate the central nerve injury of children.High dose treatment can more effectively reduce serum NSE level,and shorten the antifebrile time and rash resolution time.